報價延遲最少15分鐘:2025/07/01 06:25 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-161.50/-1.18
|
|
企業價值
2.52M
|
| 資產負債 |
|
每股賬面淨值
7.65
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/01 06:25 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |